IPP Bureau
Avient expands healthcare TPU manufacturing in China
By IPP Bureau - September 27, 2024
Showcases specialty and sustainable materials for healthcare at Medtec China 2024
India highlights need for global cooperation to address AMR threat at UNGA
By IPP Bureau - September 27, 2024
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
Rockwell study highlights need for highly skilled workforce for life sciences
By IPP Bureau - September 27, 2024
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Zydus and CSIR-CDRI Lucknow to develop drug for CKD induced Osteoporosis
By IPP Bureau - September 27, 2024
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Alkem denies claims of Pan-D, Clavam 625 batches being substandard quality
By IPP Bureau - September 27, 2024
The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem
Alembic receives USFDA final approval for Paliperidone ER tablets
By IPP Bureau - September 27, 2024
Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for treatment of schizophrenia
Briefs: Krsnaa Diagnostics and Anuh Pharma
By IPP Bureau - September 27, 2024
Krsnaa Diagnostics receives LoI from RINPAS for radiology services
USV launches Q rite tablets for treatment of rare aprhythmia in heart patients
By IPP Bureau - September 27, 2024
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Sanofi’s dupixent approved in the US as the first-ever biologic medicine for patients with COPD
By IPP Bureau - September 27, 2024
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months
By IPP Bureau - September 27, 2024
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
Granules India launches 'Breast Health Express' mobile unit
By IPP Bureau - September 26, 2024
The mobile unit "Breast Health Express" brings advanced medical technology directly to communities in need
Biocon Biologics Global to raise funds through senior secured notes
By IPP Bureau - September 26, 2024
The Notes shall not be offered or sold in India
Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as additional formulation in Japan
By IPP Bureau - September 26, 2024
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Pfizer withdraws all lots of sickle cell disease treatment voxelotor
By IPP Bureau - September 26, 2024
Pfizer's decision is based on the totality of clinical data
Decline in TB incidence by 16% from 237 per hundred thousand population in 2015 to 199 in 2022
By IPP Bureau - September 25, 2024
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
